Last reviewed · How we verify
Short-acting G-CSF
Short-acting G-CSF is a Small molecule drug developed by Lei Li. It is currently FDA-approved.
Short-acting G-CSF is used to treat conditions such as chemotherapy-induced neutropenia, febrile neutropenia, and myelosuppression in adults. It is also studied for its use in solid tumors, gynecologic cancer, and other conditions, often in conjunction with supportive care strategies.
At a glance
| Generic name | Short-acting G-CSF |
|---|---|
| Sponsor | Lei Li |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- G-CSF-Induced Bone Pain and Supportive Care Approaches
- Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy (PHASE2)
- A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency (NA)
- Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer (PHASE3)
- G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients (PHASE4)
- Long-acting G-CSF for Febrile Neutropenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short-acting G-CSF CI brief — competitive landscape report
- Short-acting G-CSF updates RSS · CI watch RSS
- Lei Li portfolio CI
Frequently asked questions about Short-acting G-CSF
What is Short-acting G-CSF?
Who makes Short-acting G-CSF?
What development phase is Short-acting G-CSF in?
Related
- Manufacturer: Lei Li — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing